|
|
||||||||||
|
J Am Coll Cardiol, 2002; 40:1919-1927 © 2002 by the American College of Cardiology Foundation |



* Division of Cardiovascular Diseases, Rochester, Minnesota, USA
Division of Anatomic Pathology, Rochester, Minnesota, USA
Division of Hypertension Mayo Clinic Rochester, Rochester, Minnesota, USA
Unit of Biochemistry, Faculty of Medicine and the Rapport Institute for Research in Medical Sciences, Technion-Israel Institute of Technology, Haifa, Israel
Manuscript received May 10, 2002; revised manuscript received July 16, 2002, accepted July 24, 2002.
* Reprint requests and correspondence: Dr. Amir Lerman, Division of Cardiovascular Diseases, Mayo Clinic Rochester, 200 First Street SW, Rochester, Minnesota USA55905.
lerman.amir{at}mayo.edu
OBJECTIVES: The current study was designed to examine whether ubiquitin expression is higher in unstable than in stable lesions of patients with acute coronary syndrome (ACS).
BACKGROUND: The ubiquitin system has been identified as the nonlysosomal pathway of protein degradation; it is involved in a number of biologic processes crucial to cell and tissue integrity and therefore, might be potentially involved in the rupture of unstable coronary plaques.
METHODS: We conducted an autopsy-based study of 25 consecutive patients with fatal ACS. Lesions of both infarct-related and noninfarct-related segments from the same patients were examined for the expression and localization of ubiquitin by use of immunohistochemistry and a semiquantitative grading scale.
RESULTS: Ubiquitin immunoreactivity was higher in infarct-related than in noninfarct-related lesions (1.4 ± 0.5 vs. 1.1 ± 0.6, p = 0.03). Compared with areas adjacent to the plaque (0.6 ± 0.7), ubiquitin immunoreactivity was higher in areas around the lipid core (2.5 ± 0.8, p < 0.001), plaque shoulders (1.6 ± 1.1, p < 0.001), and fibrous cap regions (1.6 ± 1.1, p < 0.001). Within the plaque area, co-localization of ubiquitin immunoreactivity with T cells and macrophages was found. In areas adjacent to the plaque, ubiquitin immunoreactivity co-localized with neointima cells and media smooth muscle cells.
CONCLUSIONS: In patients with ACS, ubiquitin immunoreactivity is enhanced in unstable, infarct-related lesions, predominantly in plaque regions of tissue degradation. Based on these findings, this study suggests a role for the ubiquitin system in the destabilization and rupture of coronary atherosclerotic plaques in humans.
| ||||||||||||||
This article has been cited by other articles:
![]() |
J. Herrmann, S. M. Soares, L. O. Lerman, and A. Lerman Potential Role of the Ubiquitin-Proteasome System in Atherosclerosis: Aspects of a Protein Quality Disease J. Am. Coll. Cardiol., May 27, 2008; 51(21): 2003 - 2010. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Takami, H. Nakagami, R. Morishita, T. Katsuya, H. Hayashi, M. Mori, H. Koriyama, Y. Baba, O. Yasuda, H. Rakugi, et al. Potential Role of CYLD (Cylindromatosis) as a Deubiquitinating Enzyme in Vascular Cells Am. J. Pathol., March 1, 2008; 172(3): 818 - 829. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Herrmann, A. M. Saguner, D. Versari, T. E. Peterson, A. Chade, M. Olson, L. O. Lerman, and A. Lerman Chronic Proteasome Inhibition Contributes to Coronary Atherosclerosis Circ. Res., October 26, 2007; 101(9): 865 - 874. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Xu, Y. Wu, P. Song, M. Zhang, S. Wang, and M.-H. Zou Proteasome-Dependent Degradation of Guanosine 5'-Triphosphate Cyclohydrolase I Causes Tetrahydrobiopterin Deficiency in Diabetes Mellitus Circulation, August 21, 2007; 116(8): 944 - 953. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Herrmann, L. O. Lerman, and A. Lerman Ubiquitin and Ubiquitin-Like Proteins in Protein Regulation Circ. Res., May 11, 2007; 100(9): 1276 - 1291. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Versari, J. Herrmann, M. Gossl, D. Mannheim, K. Sattler, F. B. Meyer, L. O. Lerman, and A. Lerman Dysregulation of the Ubiquitin-Proteasome System in Human Carotid Atherosclerosis Arterioscler. Thromb. Vasc. Biol., September 1, 2006; 26(9): 2132 - 2139. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Marfella, M. D'Amico, C. Di Filippo, A. Baldi, M. Siniscalchi, F. C. Sasso, M. Portoghese, O. Carbonara, B. Crescenzi, P. Sangiuolo, et al. Increased Activity of the Ubiquitin-Proteasome System in Patients With Symptomatic Carotid Disease Is Associated With Enhanced Inflammation and May Destabilize the Atherosclerotic Plaque: Effects of Rosiglitazone Treatment J. Am. Coll. Cardiol., June 20, 2006; 47(12): 2444 - 2455. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Marfella, M. D'Amico, K. Esposito, A. Baldi, C. Di Filippo, M. Siniscalchi, F. C. Sasso, M. Portoghese, F. Cirillo, F. Cacciapuoti, et al. The Ubiquitin-Proteasome System and Inflammatory Activity in Diabetic Atherosclerotic Plaques: Effects of Rosiglitazone Treatment Diabetes, March 1, 2006; 55(3): 622 - 632. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. R. Chade, J. Herrmann, X. Zhu, J. D. Krier, A. Lerman, and L. O. Lerman Effects of Proteasome Inhibition on the Kidney in Experimental Hypercholesterolemia J. Am. Soc. Nephrol., April 1, 2005; 16(4): 1005 - 1012. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Martinet, M. De Bie, D. M. Schrijvers, G. R.Y. De Meyer, A. G. Herman, and M. M. Kockx 7-Ketocholesterol Induces Protein Ubiquitination, Myelin Figure Formation, and Light Chain 3 Processing in Vascular Smooth Muscle Cells Arterioscler. Thromb. Vasc. Biol., December 1, 2004; 24(12): 2296 - 2301. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Herrmann, A. Ciechanover, L. O Lerman, and A. Lerman The ubiquitin-proteasome system in cardiovascular diseases--a hypothesis extended Cardiovasc Res, January 1, 2004; 61(1): 11 - 21. [Abstract] [Full Text] [PDF] |
||||
| HOME | SUBSCRIPTIONS | CURRENT ISSUE | PAST ISSUES | CARDIOSOURCE | SEARCH | HELP | FEEDBACK |